Patents by Inventor Ronald K. Scheule
Ronald K. Scheule has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020042383Abstract: Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity.Type: ApplicationFiled: September 9, 1999Publication date: April 11, 2002Inventors: NELSON S. YEW, MALGORZATA PRZBYLSKA, JOHN MARSHALL, RONALD K. SCHEULE, JENNIFER TOUSIGNANT, SENG H. CHENG
-
Publication number: 20020013282Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.Type: ApplicationFiled: October 5, 1998Publication date: January 31, 2002Inventors: JOHN MARSHALL, DAVID J. HARRIS, EDWARD R. LEE, CRAIG S. SIEGEL, SIMON J. EASTMAN, CHAU-DUNG CHANG, RONALD K. SCHEULE, SENG H. CHENG
-
Patent number: 6331524Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: April 7, 1997Date of Patent: December 18, 2001Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, David J. Harris, Edward R. Lee, Craig S. Siegel, Chau-Dung Chang, S. Catherine Hubbard, Duane E. Johnson, Daniel C. Maneval, H. Michael Shepard, Richard J. Gregory
-
Publication number: 20010048940Abstract: The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting agents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent is usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian cells.Type: ApplicationFiled: June 18, 1999Publication date: December 6, 2001Inventors: JENNIFER D. TOUSIGNANT, SIMON J. EASTMAN, EDWARD R. LEE, RONALD K. SCHEULE, SENG H. CHENG, J. NIETUPSKI, QIUMING CHU, JOHN MARSHALL
-
Patent number: 6071890Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 19, 1995Date of Patent: June 6, 2000Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, Nelson S. Yew, David J. Harris, Edward R. Lee, Craig S. Siegel
-
Patent number: 5948767Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: July 12, 1996Date of Patent: September 7, 1999Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, Nelson S. Yew, David J. Harris, Edward R. Lee, Craig S. Siegel, Chau-Dung Chang, S. Catherine Hubbard
-
Patent number: 5939401Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.Type: GrantFiled: July 15, 1996Date of Patent: August 17, 1999Assignee: Genzyme CorporationInventors: John Marshall, David J. Harris, Edward R. Lee, Craig S. Siegel, Simon J. Eastman, Chau-Dung Chang, Ronald K. Scheule, Seng H. Cheng
-
Patent number: 5935936Abstract: Novel compositions are provided. Typically, the compositions comprise one or more neutral co-lipids and also a cationic amphiphile. Therapeutic compositions are prepared according to the practice of the invention by contacting a therapeutically active molecule with a dispersion of neutral co-lipid(s) and amphiphile(s).Type: GrantFiled: June 3, 1996Date of Patent: August 10, 1999Assignees: Genzyme Corporation, University of IowaInventors: Allen J. Fasbender, Michael J. Welsh, Craig S. Siegel, Edward R. Lee, Chau-Dung Chang, John Marshall, Seng H. Cheng, David J. Harris, Simon J. Eastman, Shirley C. Hubbard, Mathieu B. Lane, Eric A. Rowe, Ronald K. Scheule, Nelson S. Yew
-
Patent number: 5910487Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: June 8, 1999Assignee: Genzyme CorporationInventors: Nelson S. Yew, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule, David J. Harris, Edward R. Lee, Craig S. Siegel
-
Patent number: 5840710Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: November 24, 1998Assignee: Genzyme CorporationInventors: Edward R. Lee, David J. Harris, Craig S. Siegel, Mathieu B. Lane, Shirley C. Hubbard, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule
-
Patent number: 5783565Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: February 1, 1996Date of Patent: July 21, 1998Assignee: Genzyme CorporationInventors: Edward R. Lee, David J. Harris, Craig S. Siegel, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule
-
Patent number: 5747471Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 11, 1995Date of Patent: May 5, 1998Assignee: Genzyme CorporationInventors: Craig S. Siegel, David J. Harris, Edward R. Lee, Shirley C. Hubbard, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule, Mathieu B. Lane, Eric A. Rowe
-
Patent number: 5719131Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: February 17, 1998Assignee: Genzyme CorporationInventors: David J. Harris, Edward R. Lee, Craig S. Siegel, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule